Wockhardt adds another 8,700 bottles to Toprol recall; ABPI board clears Novo employees after complaint;

@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Report | Follow @FiercePharma

@TracyStaton: Would you pay $84K for Sovaldi yourself if you had hep C? Check out this discussion FiercePharma's LinkedIn group. More | Follow @TracyStaton

@EricPFierce: Interesting dissection of Valeant's 'opaque' biz model from ProPublica's Jesse Eisinger. Story | Follow @EricPFierce

@CarlyHFierce: Russia mulls taking $300M in state vaccine contracts local. FierceVaccines story | Follow @CarlyHFierce

@JustinHFierce: Zoetis Animal Health $ZTS traded up 0.35% during mid-day and hit $31.36, upgraded by Zacks from an underperform. More | Follow @JustinHFierce

> India's Wockhardt issued yet another recall of generic Toprol XL, pulling more than 8,000 bottles of the hypertension remedy because tablets failed a dissolution test. Report

> The Association of the British Pharmaceutical Industry's compliance watchdog cleared Novo Nordisk ($NVO) of any wrongdoing after investigating a complaint about three of its employees. Report

> Novo Nordisk ($NVO) said the government of Québec added Victoza, its GLP-1 diabetes treatment, to its reimbursement formulary. Release

> Ironwood Pharmaceuticals ($IRWD) chose Douglas Williams, EVP of research and development at Biogen Idec ($BIIB), to serve on its board of directors. Release

> As Nestlé moves more deeply into health-related products that require big investments in development, it's less tolerant of its low-performing food brands. Report

> The Chinese drugmaker Kangmei Pharma plans to plow 800 million yuan ($128 million) into a ginseng project. Report

Medical Device News

@FierceMedDev: Medtronic considers bid for Smith & Nephew amid building med dev merger mania. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Surgical instruments that improve cellulite will get FDA downgrade. Article | Follow @VarunSaxena2

@MichaelGFierce: Singapore team designs nanotechnology glaucoma treatment for sustained release. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Mind-controlled exoskeleton with a 3D-printed helmet could make its debut at the World Cup opening ceremony. Story from The Atlantic | Follow @EmilyWFierce

> Delaying valve replacement procedures could adversely impact high-risk patients. Article

> Study supports clinical guidelines on ICD usage. Story

Biotech News

@FierceBiotech: Join 's & 's today, 2pm ET for an chat. Follow . | Follow @FierceBiotech

@JohnCFierce: ICYMI yesterday: Trevi, Complexa bag $38M in VC cash to hit the gas on R&D. Story | Follow @JohnCFierce

@DamianFierce: Forgot @BayerHealthCare's pharma boss is leaving for International Flavors & Fragrances, which sounds like smthng RZA would boast of having. | Follow @DamianFierce

@EmilyMFierce: ICYMI: Nektar reports tumor reduction in preclinical study. Story from FierceBiotech Research | Follow @EmilyMFierce

> GlaxoSmithKline tees up another huge cardio PhIII after darapladib flop. Article

> Boehringer's IPF drug hits the EU fast track in race with InterMune. Story

> FierceBiotech and the experts weigh in on surviving the proof-of-concept challenge. Editor's Corner

> Analysts: Shire must go shopping to stay independent. Report

Vaccines News

> GAVI nets $50M for Merck's Gardasil, GSK's Cervarix. News

> Scripps, U. of Nebraska-Lincoln win $15M to advance HIV vaccines. Article

> PharmAthene anthrax vax aces survival in rabbit study. Item

> Study: Cholera vaccine has 86% effectiveness rate. Story

> Amgen to pursue T-Vec approval despite PhIII survival miss. More

Pharma Manufacturing News

> Vietnam bans products from 45 Indian companies for failing to meet standards. Item

> Turkey's drugmakers expand manufacturing as market booms. More

> Amneal said to be negotiating to buy Indian sterile injectable manufacturer. Report

> Glenmark opens new mAb manufacturing facility in Switzerland. Article

> AbbVie API expansion in Ireland readies it for anticipated hep C treatment. Story

And Finally... Should Apple ($AAPL) and Google ($GOOG) police the health-and-fitness apps sold via its marketplaces? Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.